Abstract
Obesity is a worldwide pandemic and has become a major concern both as a public health issue and an economic burden. Insulin resistance is a common denominator of obesity, and Type 2 DM affecting the liver, pancreatic beta-cell, skeletal muscles. Active compound berberine (BBR) in Chelidonium majus has been investigated previously on various metabolic pathways. However, Homeopathic preparations of Chelidonium majus (HPCM) with active compound BBR has not been investigated to manage obesity and Type 2 DM. As the pancreas and liver share similar regenerating factors, they can be further investigated as a target site for deciphering the mechanism of action of HPCM in obesity and Type 2 DM. Therefore, we hypothesize that HPCM at ultra-low concentrations might show anti-obesity action that may act by either activating AMP protein kinase pathway or inhibition of phosphodiesterase in adipocytes or inhibition of hepatic lipogenesis or by promoting fatty acid beta-oxidation in skeleton muscles. We further hypothesize that, the same drug might show anti-diabetic activity by enhancing insulin secretion or by stimulating glycolysis, or suppressing adipogenesis by inhibiting PPAR gamma and C/EBP alpha function. The dual activity of HPCM may be attributed to synergistic action of all the active ingredients in ultra-low concentration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
